TickerFacts.

Xilio Therapeutics, Inc. (XLO): Revenue

Annual figures by period end, from SEC filings.

$43.77M
Year ended 2025-12-31
$64.09M
Trailing 12 months to 2026-06-30
2024-12-31: $6.34M2025-12-31: $43.77M$43.77M
2024-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$43.77M+589.9%2026-03-23, From 2025-01-01
2024-12-31$6.34Mn/a2026-03-23, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Xilio Therapeutics, Inc. (XLO)2025-12-31$43.77M+589.9%
Integrated Biopharma Inc (INBP)2026-06-30$43.87M-19.3%
Cumberland Pharmaceuticals Inc (CPIX)2025-12-31$44.52M+17.6%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$44.55M-22.6%
Wave Life Sciences, Inc. (WVE)2025-12-31$42.73M-60.5%
Biofrontera Inc. (BFRI)2025-12-31$41.70M+11.7%
Septerna, Inc. (SEPN)2025-12-31$45.95Mn/m
Protagonist Therapeutics, Inc (PTGX)2025-12-31$46.02M-89.4%
Gossamer Bio, Inc. (GOSS)2025-12-31$48.47M-57.7%

Compare XLO, INBP, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗